Cancer Therapeutics Market-Size, Share, Trends & Forecast to 2034

Cancer Therapeutics Market Data Product Overview

The Cancer Therapeutics Market data product covers market size and forecasts, therapy types, cancer types, key drugs, end-users, regional dynamics and competitive activity across oncology. The market is projected to reach USD 326.05 billion by 2034, with a 9.4% CAGR stated for 2025–2030. Coverage includes chemotherapy, targeted therapy, immunotherapy, hormonal therapy and other therapies, as well as blood, breast, prostate, gastrointestinal, gynaecologic, respiratory/lung and other cancers. The report combines primary expert interviews conducted on an aggregated basis with secondary research from proprietary databases and industry journals.

Use Cases

• Market entry sizing: Assess oncology opportunity by therapy type, cancer type, end-user and geography, including chemotherapy, immunotherapy, targeted therapy, hospitals, specialty clinics and cancer and radiation therapy centers.

• Competitive benchmarking: Compare strategic positioning across 15 companies profiled in the report, including Novartis AG, AbbVie Inc., Roche, Pfizer Inc. and AstraZeneca.

• M&A target screening: Evaluate competitive activity and strategic moves such as AbbVie’s CERVINO Phase 3 trial and Novartis’s acquisition of Mariana Oncology in the oncology therapeutics landscape.

• Vendor evaluation: Assess therapy and product-market opportunities across key drugs including Keytruda, Darzalex, Revlimid, Avastin and Herceptin, alongside regional market dynamics.

Metadata

• Update Frequency: One-time syndicated research publication.

• Data Source(s): Primary interviews + secondary research (proprietary databases, industry journals), with findings presented on an aggregated basis.

• Original Publisher of data: Next Move Strategy Consulting

• Geographic coverage: North America, Europe, Asia-Pacific, and Rest of World (RoW).

• Is historical data "point-in-time": Historical figures are point-in-time as of publication; forecast figures are projections.

• Data Set(s) Format(s): PDF / Excel

• Raw or scraped data: No syndicated analyst research.

• Number of companies/brands covered: 15 Companies.

Key Data Points

• Rising prevalence of chronic diseases, including cancer and tumours, is a key market growth driver.

• An aging population is increasing demand for cancer therapeutics as cancer risk rises with age.

• Technological advances in oncology, including immunotherapy, targeted medicine and next-generation antibody-drug conjugates, are supporting market development.

Pricing Information

Pricing is provided through the AWS Data Exchange offer. License-tier availability

Regulatory and Compliance Information

This report is built from aggregated, publicly available, and licensed secondary sources plus expert interviews conducted on an aggregated basis. It contains no individually identifiable personal data.

Subscription Verification

AWS Data Exchange requires subscription verification on all public offers (subscribers confirm they're not in a restricted country or a covered party).